肝纤维化的血清学诊断研究进展*

doi:10.3969/j.issn.1672-5069.2016.01.036

摘要/Abstract

摘要： 肝纤维化是各种不同病因慢性肝病向终末期肝病进展的必经阶段。近年来,肝纤维化的血清学诊断因其无创性和重复性好而得到广泛的重视。肝纤维化的血清学诊断包括血清常规肝纤维化标志物、血清诊断模型、组学和基因学等方法,而两种或两种以上的血清学诊断方法和模型的联合应用将有助于提高肝纤维化及肝硬化的诊断准确性,从而试图避免临床肝活检。

关键词: 肝纤维化, 血清学标志物, 诊断

Abstract: Liver fibrosis is an inevitable process of chronic liver diseases with different causes which might lead to end-stage liver diseases. In recent years, the serologic diagnosis of liver fibrosis gets widely attention for its non-invasiveness and good repeatability. The serologic diagnosis of liver fibrosis includes conventional serologic markers,serologic diagnostic models, omics,genetics,and the joint application of two or more methods.

Key words: Liver fibrosis, Serologic markers, Diagnosis

刘婷综述, 徐铭益审校. 肝纤维化的血清学诊断研究进展^*[J]. 实用肝脏病杂志, 2016, 19(1): 125-128.

Liu Ting, Xu MingYi. Serologic diagnosis of liver fibrosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(1): 125-128.

参考文献

[1] Patel1 K,Bedossa P,Castera L. Diagnosis of liver fibrosis: Present and future. Liver Dis,2015,35（2）:166-183.
[2] Baranova A,Lal P,Birerdinc A,et al. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol,2011,11（12）:91-135.
[3] Benyon RC,Arthur MJ. ExtraceUular matrix degradation and the role of hepatic stellate ceas. Semin Liver Dis,2001,21（3）:373-384.
[4] Walsh KM,Fletcher A,MacSween RN,et al. Basement membrane peptides as markers of liver disease in chronic hepatitis C. J Hepatol,2000,32（2）:325-330.
[5] Roderfeld M,Hemmann S,Roeb E. Mechanisms of fibrinolysis in chronic liver injury （with special emphasis on MMPs and TIMPs）. Z Gastroenterol,2007,45（1）:25-33.
[6] Schwettmann L,Wehmeier M,Jokovic D,et al. Hepatic expression of a disintegrin and metalloproteinase（ADAM） and ADAMs with thrombospondin motives（ADAM-TS） enzymes in patients with chronic liver disease. J Hepatol,2008,49（2）:243-250.
[7] Boeker KH,Haberkom CI,Michels D,et al. Diagnostic potential of circulating TIMP-l and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta,2002,316（1-2）:7l-81.
[8] 徐铭益,陆伦根. 肝纤维化血清学标志物及诊断模型的诊断价值. 中华肝脏病杂志,2014,22（9）:647-649.
[9] Imbert-Bismut F,Ratziu V,Pieroni L,et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection:A prospective study. Lancet,2001,357（9262）:1069-1075.
[10] Forns X,Ampurdanes S,Llovet JM,et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatoogy,2002,36（4 Pt 1）:986-992.
[11] Cales P,Oberti F,Michalak S,et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology,2005,42（6）:1373-1381.
[12] Adams LA,Bulsara M,Rossi E,et al. Hepascore:An accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem,2005,51（10）:1867-1873.
[13] Zeng MD,Lu LG,Mao YM,et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology,2005,42（6）:1437-1445.
[14] Qu Y,Gao CF,Zhou K,et al. Serum N-glycomic markers in combination with panels improves the diagnosis of chronic hepatitis B. Ann Hepatol,2012,11（2）:202-212.
[15] Wang Y,Xu MY,Zheng RD,et al. Prediction of significant fibrosis and cirrhosis in hepatitis B e-antigen negative patients with chronic hepatitis B using routine parameters. Hepatol Res,2013,43（5）:441-451.
[16] Zhou K,Gao CF,Zhao YP,et al. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. J Gastroenterol Hepatol,2010,25（9）:1569-1577.
[17] Sebastiani G,Vario A,Guido M,et al. Sequential algorithms combining noninvasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol,2007,13（4）:525-531.
[18] Sebastiani G,Halfon P,Castera L,et al. SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology,2009,49（6）:1821-1827.
[19] Naveau S,Gaude G,Asnacios A,et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology,2009,49（1）:97-105.
[20] Guha IN,Parkes J,Roderick P,et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease:Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology,2008,47（2）:455-460.
[21] Mayo MJ,Parkes J,Adams-Huet B,et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology,2008,48（5）:1549-1557.
[22] Crawford DH,Murphy TL,Ramm LE,et al. Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology,2009,49（2）:418-425.
[23] XU MY,QU Y,JIA XF,et al. Serum proteomic MRM identify peptideions of transferrin as new fibrosis markers in chronic hepatitis B. Biomed Pharmacother,2013,67（7）:561-567.
[24] Qu Y,Gao CF,Zhou K,et al. Serum N-glycomic markers in combination with panels improves the diagnosis of chronic hepatitis B. Ann Hepatol,2012,11（2）:202-212.
[25] Xu MY,Jia XF,Qu Y,et al. Serum dihydroxyacetone kinase peptide m/z 520.3 as predictor of disease severity in patients with compensated chronic hepatitis B. J Transl Med,2013,11（9）:234.
[26] Venugopal SK,Jiang J,Kim TH,et al. Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells,and their overexpression causes decreased stellate cell activation. Am J Physiol Gastrointest Liver Physiol,2010,298（1）:G101-G106.
[27] Guo CJ,Pan Q,Li DG,et al. miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell:An essential role for apoptosis. J Hepatol,2009,50（4）:766-778.
[28] Murakami Y,Toyoda H,Tanaka M,et al. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One,2011,6（1）:e16081.
[29] Ninomiya M,Kondo Y,Funayama R,et al. Distinct microRNAs expression profile biliary cirrhosis and evaluation of miR-505-3P and miR-197-3p as novel biomarkers. PLoS One,2013,8（6）:e66086.
[30] 徐铭益,张启迪,李郑红,等. 慢性乙型肝炎肝纤维化患者肝组织基因表达谱和功能分类. 肝脏,2013,18（7）：435-438.
[31] Schuppan D,Pinzani M. Anti-fibrotic therapy: lost in translation? J Hepatol,2012,56（1）:66-77.
[32] Trepo E,Potthoff A,Pradat P,et al. Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. J Hepatol,2011,55（1）:38-44.
[33] Estrabaud E,Vidaud M,Marcellin P,et al. Genomics and HCV infection:progression of fibrosis and treatment response. J Hepatol,2012,57（5）:1110-1125.
[34] Dongiovanni P,Donati B,Fares R,et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol,2013,19（41）:6969-6978.
[35] Hannivoort RA,Hernandez-Gea V,Friedman SL. Genomics and proteomics in liver fibrosis and cirrhosis. Fibrogen Tissue Rep,2012,5（1）:1.

肝纤维化的血清学诊断研究进展^*

Serologic diagnosis of liver fibrosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[2]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[5]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[6]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[7]	曾艳妮, 张灿, 毕俊英, 刘良进, 孟俊, 秦涛. MRI长时间延迟增强扫描诊断肝脏孤立性坏死性结节价值研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 900-903.
[8]	邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.
[9]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.
[10]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[11]	黄汉军, 鲁凤荣, 张灿. 基于Exchange血流动力学模型的MRI扫描参数诊断肝硬化临床价值分析*[J]. 实用肝脏病杂志, 2019, 22(5): 696-699.
[12]	洪佳, 吴晓宁, 尤红. 胆汁淤积性肝病的规范化诊断[J]. 实用肝脏病杂志, 2019, 22(5): 758-760.
[13]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[14]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[15]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.